{"id":"ab-sa01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:02:02.231729","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AB-SA01 works by binding to specific lipopolysaccharides on the surface of Gram-negative bacteria, ultimately leading to cell lysis and death. This mechanism of action is distinct from traditional antibiotics, which often target specific enzymes or proteins within bacterial cells.","oneSentence":"AB-SA01 is a novel antimicrobial agent that targets and disrupts bacterial cell membranes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:09.392Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of complicated urinary tract infections caused by Gram-negative bacteria"}]},"_fixedFields":["pubmed(7)"],"trialDetails":[{"nctId":"NCT03395769","phase":"","title":"Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic","status":"NO_LONGER_AVAILABLE","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"","conditions":"","enrollment":""},{"nctId":"NCT02757755","phase":"PHASE1","title":"Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults","status":"COMPLETED","sponsor":"Armata Pharmaceuticals, Inc.","startDate":"2016-05","conditions":"Healthy Volunteers","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"recentPublications":[{"date":"2024 Feb 12","pmid":"38347019","title":"Lytic activity of phages against bacterial pathogens infecting diabetic foot ulcers.","journal":"Scientific reports"},{"date":"2020 Dec 16","pmid":"33077648","title":"Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model.","journal":"Antimicrobial agents and chemotherapy"},{"date":"2020 Jul 9","pmid":"32646376","title":"Efficacy of phage cocktail AB-SA01 therapy in diabetic mouse wound infections caused by multidrug-resistant Staphylococcus aureus.","journal":"BMC microbiology"},{"date":"2020 May 18","pmid":"32443619","title":"Efficacy of Lytic Phage Cocktails on Staphylococcus aureus and Pseudomonas aeruginosa in Mixed-Species Planktonic Cultures and Biofilms.","journal":"Viruses"},{"date":"2020 Mar","pmid":"32066959","title":"Safety of bacteriophage therapy in severe Staphylococcus aureus infection.","journal":"Nature microbiology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AB-SA01","genericName":"AB-SA01","companyName":"Armata Pharmaceuticals, Inc.","companyId":"armata-pharmaceuticals-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AB-SA01 is a novel antimicrobial agent that targets and disrupts bacterial cell membranes. Used for Treatment of complicated urinary tract infections caused by Gram-negative bacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}